Applied Therapeutics Inc.

NASDAQ: APLT · Real-Time Price · USD
0.48
-0.03 (-5.70%)
At close: Jul 25, 2025, 3:59 PM

Applied Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
265K 455K -211K -333K -477K 9.99M 10.66M 10.66M 10.66M n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
202K 321K 588K 706K 699K 580K 346K 339K 333K 441K 435K 428K 423K 415K 308K 204K 100K
Gross Profit
64K 135K -799K -1.04M -1.18M 9.41M 10.31M 10.32M 10.33M -441K -435K -428K -423K -415K -308K -204K -100K
Operating Income
-108.73M -104.3M -92.28M -78.04M -74.77M -64.54M -62.5M -66.36M -70.71M -82.95M -91.09M -100.17M -104.52M -105.62M -102.25M -103.79M -106.19M
Interest Income
3.57M 3.53M 2.92M 1.96M 1.74M 1.37M 1.48M 1.31M 1.02M 872K 414K 263K 321K 245K 369K 424K 255K
Pretax Income
-43.51M -105.62M -187.31M -161.09M -193.56M -119.76M -96.51M -73.24M -69.52M -82.51M -95.24M -104.56M -104.53M -105.58M -102.11M -103.54M -105.77M
Net Income
-43.51M -105.62M -187.31M -161.09M -193.56M -119.76M -87.9M -64.34M -69.09M -82.02M -103.36M -112.97M -104.47M -105.58M -102.11M -103.54M -105.77M
Selling & General & Admin
64.43M 55.81M 39.6M 29.27M 24.11M 20.62M 22.47M 24M 24.83M 27.32M 31.83M 36.42M 41.37M 43.05M 41.59M 40.78M 37.23M
Research & Development
44.36M 36.72M 40.33M 36.28M 38.16M 53.91M 50.7M 53.03M 56.54M 55.63M 59.27M 63.75M 63.15M 62.57M 60.66M 63.01M 68.97M
Other Expenses
-34K -60K -121K -111K -82K -56K 22K 4K -81K -177K -473K -529K -561K -521K -307K -253K -93K
Operating Expenses
108.87M 92.61M 79.92M 65.55M 62.27M 74.53M 73.16M 77.02M 81.37M 82.95M 91.09M 100.17M 104.52M 105.62M 102.25M 103.79M 106.19M
Interest Expense
n/a n/a 721K 721K 721K 721K n/a n/a 111K 187K 742K 818K 876K 876K 880K 935K 949K
Selling & Marketing Expenses
-122K -122K -122K -122K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
109M 104.75M 92.07M 77.7M 74.3M 74.53M 73.16M 77.02M 81.37M 82.95M 91.09M 100.17M 104.52M 105.62M 102.25M 103.79M 106.19M
Income Tax Expense
n/a n/a -11.56M -11.68M 721K 721K 3.67M 3.49M -429K -485K 7.62M 7.83M -811K -831K -322K -377K -390K
Shares Outstanding (Basic)
144.79M 139.53M 14.43M 49.34M 49.34M 84.24M 90.67M 79.04M 56.32M 48.06M 48M 26.9M 26.22M 25.97M 26.18M 26.08M 24.14M
Shares Outstanding (Diluted)
144.79M 139.53M 14.43M 49.34M 49.34M 84.24M 90.67M 79.04M 56.36M 48.06M 48M 26.9M 26.22M 26.18M 26.18M 26.08M 24.14M
EPS (Basic)
-4.52 -6.07 -6.84 -2.56 -2.99 -1.47 -1.14 -1.06 -1.97 -2.67 -3.6 -4.3 -4.01 -4.13 -4.06 -4.3 -4.58
EPS (Diluted)
-4.52 -6.07 -6.84 -2.56 -2.99 -1.47 -1.14 -1.06 -1.97 -2.67 -3.59 -4.29 -4 -4.12 -4.06 -4.3 -4.58
EBITDA
-108.44M -104.11M -92.18M -78.03M -74.77M -64.42M -62.39M -66.14M -70.48M -82.75M -90.83M -99.91M -104.11M -105.18M -101.72M -103.26M -105.73M
EBIT
-108.73M -104.3M -92.28M -78.04M -74.77M -64.54M -62.5M -66.36M -70.71M -82.95M -91.09M -100.17M -104.52M -105.62M -102.25M -103.79M -106.19M
Depreciation & Amortization
410K 425K 351K 365K 358K 353K 460K 453K 447K 441K 435K 428K 423K 415K 407K 398K 387K